Clinical Trials Sponsored by Espero Biopharma

Total 1526 results

Espero Biopharma

Unknown

Tecarfarin Anti-Coagulation Trial (TACT) (TACT)

Thrombosis | Thromboembolism
Spero Therapeutics

Recruiting

A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SPR720 as Compared With Placebo for the Treatment of Participants With Mycobacterium Avium Complex (MAC) Pulmonary Disease

Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)

United States
Spero Therapeutics

Completed

A Study to Assess the Intrapulmonary Pharmacokinetics (PK) of SPR719 by Comparing the Plasma, Epithelial Lining Fluid, and Alveolar Macrophage Concentrations Following the Oral Administration of Multiple Doses of SPR720 in Healthy Volunteers.

Healthy Volunteer

United States
Spero Therapeutics

Completed

A Study to Compare Two Bioanalytical Assays for Tebipenem

Healthy Volunteers

United States
Spero Therapeutics

Completed

Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) (ADAPT-PO)

Acute Pyelonephritis | Complicated Urinary Tract Infection

Bulgaria, Georgia, United States, Czechia, Estonia, Hungary, Latvia, Moldova, Republic of, Poland, Romania, Russian Federation, Serbia, Slovakia, South Africa, Ukraine
Spero Therapeutics

Terminated

Safety, Tolerability, Pharmacokinetics and Efficacy of SPR720 for the Treatment of Patients With Mycobacterium Avium Complex (MAC) Pulmonary Disease

Mycobacterium Avium Complex | Non-tuberculous Mycobacterium Pulmonary Disease

United States
Spero Therapeutics

Completed

Phase 1 Study of PK and Safety of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Subjects With Various Degrees Of Renal Function

Renal Impairment

United States
Spero Therapeutics

Completed

Bioequivalence Study Comparing Two Tablet Formulations of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Healthy Adult Subjects

Healthy Volunteers

United States
Spero Therapeutics

Completed

A Study to Evaluate the Effect of Co-administration on the Pharmacokinetics of SPR720, Azithromycin, and Ethambutol in Healthy Participants

Healthy Volunteers

United States
Spero Therapeutics

Completed

Study to Examine the Effect of Antacid and Omeprazole on the Single-Dose Pharmacokinetics of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Healthy Adult Subjects

Healthy Volunteers

United States
Spero Therapeutics
Clinartis

Completed

Study to Assess the Intrapulmonary Pharmacokinetics of SPR859 by Comparing the Plasma, Epithelial Lining Fluid (ELF), and Alveolar Macrophages (AM) Concentrations Following the Oral Administration of Five Doses of SPR994 in Healthy, Nonsmoking Volunteers

Healthy Volunteers

United States
Spero Therapeutics
Celerion

Completed

A Single-Dose, Randomized, Placebo- and Active-Control, Four-Way, Cross-Over Study for the Evaluation of the Effect of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) on the QT/QTc Intervals in Adult Healthy Subjects

TQT Study

United States
Spero Therapeutics
GlaxoSmithKline

Recruiting

A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) (PIVOT-PO)

Urinary Tract Infection | Acute Pyelonephritis

Moldova, Republic of, Georgia, United States, Serbia, Bulgaria, Romania, South Africa
Spero Therapeutics
Covance

Completed

Study of the Absorption, Metabolism, and Excretion of [14C]-Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) Following a Single Oral Dose in Healthy Male Subjects

Healthy Volunteers

United States
Hartford Hospital
Spero Therapeutics

Completed

Bioavailability of Tebipenem (SPR994) Crushed Tablet

Relative Bioavailability

United States
Hartford Hospital
Spero Therapeutics

Completed

Tebipenem (SPR994) Tissue Penetration in Diabetic Patients With Wound Infections and Healthy Volunteers Via In Vivo Microdialysis

Diabetes | ABSSSI | Healthy Volunteers | Wound Infection

United States
Spero Therapeutics
Simbec Research

Completed

A Study of the Safety, Tolerability, and Pharmacokinetics of SPR720 in Healthy Volunteers

Healthy Volunteers

United Kingdom
Spero Therapeutics
Iqvia Pty Ltd

Completed

Effect of Tebipenem on Normal Human Intestinal Microbiota

Healthy Volunteers

Sweden
University of Extremadura
Luis Espejo Antúnez

Completed

Effects of Warm up in Athletes With Previous Hamstring Injury

Previous Hamstring Injury

Spain
Vesper Biotechnologies ApS

Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VES001 in Healthy Participants (SORT-IN-1)

Dementia, Frontotemporal

Netherlands
Vesper Medical, Inc.

Active, not recruiting

Venous Stent for the Iliofemoral Vein Investigational Clinical Trial Using the DUO Venous Stent System (VIVID)

Deep Vein Thrombosis | Chronic Venous Insufficiency | May-Thurner Syndrome

United States, Poland
Esperion Therapeutics, Inc.

Completed

Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-C

Diabetes Mellitus, Type 2 | Diabetes | Cholesterolemia

United States
Esperion Therapeutics, Inc.

Completed

A Study of the Safety, Pharmacokinetic Drug Interaction and Efficacy of ETC-1002 and Atorvastatin in Subjects With Hypercholesterolemia

Hypercholesterolemia

United States
Esperion Therapeutics, Inc.

Completed

A Multiple Ascending Dose Study of ETC-1002 in Subjects With Mild Dyslipidemia

Mild Dyslipidemia

United States
Mespere Lifesciences Inc.

Unknown

Role of the Mespere Venus 1000 in Predicting Heart Failure Hospital Readmissions

ADHF

Canada
Mespere Lifesciences Inc.

Unknown

Comparison of Central Venous Oxygen Saturation Measurements by Non-invasive Mespere Venous Oximeter and Central Venous Catheter

Sepsis | Post Cardiac Surgery Low Output Syndrome Requiring Inotropic/Vasopressor Therapy | Cardiogenic Shock Post Myocardial Infarction | Hypoxemic Respiratory Failure.

Canada
Mespere Lifesciences Inc.

Completed

Correlation of Measurements From Mespere Venus 1000 System & Echocardiography to Estimate Right Atrial Pressure

Patients Referred to St. Michael's Hospital Echocardiography Lab

Canada
Hospital Severo Ochoa

Completed

A 3 Year Follow-up Prospective Open Randomized Trial of TVT Versus Colposuspension for Primary Stress Incontinence

Urinary Incontinence

Spain
Lantu Biopharma

Not yet recruiting

An Open-label Study of a Gene Therapy Product in Beta-Thalassemia

Beta-Thalassemia
Huons Biopharma

Not yet recruiting

To Evaluate HU-045 in the Treatment of Glabellar Lines(Phase III)

Glabellar Lines
Vor Biopharma

Recruiting

Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant

Leukemia, Myeloid, Acute

United States
Theravance Biopharma

Recruiting

Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy (CYPRESS)

MSA - Multiple System Atrophy | Symptomatic Neurogenic Orthostatic Hypotension

United States, Spain, United Kingdom, Hungary, Italy, Argentina, Austria, Poland, Germany, Portugal, Belgium, Brazil, Denmark, Estonia, Canada, France, Chile
United BioPharma

Not yet recruiting

Evaluating the Safety and Tolerability and Determining the PK and PD of Single Dose UB-221 in Chronic Spontaneous Urticaria

Chronic Idiopathic Urticaria
Kinnate Biopharma

Active, not recruiting

A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations

Intrahepatic Cholangiocarcinoma | Urothelial Carcinoma | Solid Tumor, Adult

United States, Korea, Republic of, Taiwan, China, Denmark, Spain
NImmune Biopharma

Terminated

Efficacy and Safety of Oral BT-11 in Moderate to Severe Crohn's Disease

Crohn's Disease

United States
CTI BioPharma

Completed

Pixantrone (BBR 2778) in Patients With Refractory Acute Myelogenous Leukemia (AML)

Acute Myelogenous Leukemia

United States
NImmune Biopharma

Completed

Safety Tolerability and Pharmacokinetics of Oral NIM-1324 in Healthy Adult Male and Female Volunteers

Normal Healthy Volunteers

Australia
NImmune Biopharma

Withdrawn

Safety and Efficacy of Oral BT-11 in Crohn's Disease Patients With Moderate to Severe Disease

Crohn's Disease
Theravance Biopharma

Terminated

Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure (OAK)

Symptomatic Neurogenic Orthostatic Hypotension

United States, Spain, Portugal, United Kingdom, France, Denmark, Ukraine, Israel, Estonia, Poland, Italy, Russian Federation, Australia, Austria, Bulgaria, Canada, Germany, New Zealand
Theravance Biopharma

Terminated

Efficacy & Safety of TD-1473 in Ulcerative Colitis (RHEA)

Ulcerative Colitis (UC)

United States, Australia, Bulgaria, Canada, France, Georgia, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Poland, Portugal, Romania, Serbia, Slovakia, South Africa, Spain, Taiwan, Ukraine
DS Biopharma

Completed

Efficacy and Safety Study of Orally Administered DS107 in Moderate to Severe Atopic Dermatitis Patients

Atopic Dermatitis

United States, South Africa
Theravance Biopharma

Completed

Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure (SEQUOIA)

Symptomatic Neurogenic Orthostatic Hypotension

United States, Spain, Israel, Hungary, Portugal, Australia, Canada, Germany, Russian Federation, Estonia, France, Italy, United Kingdom, Denmark, Poland, New Zealand, Austria, Bulgaria, Ukraine
United BioPharma

Completed

Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UB-221 as an Add-on Therapy in CSU Patients

Urticaria Chronic

Taiwan
Theravance Biopharma

Completed

Effect of Inhaled TD-8236 on Allergen-induced Asthmatic Response

Asthma

United Kingdom
Theravance Biopharma

Completed

Phase 2 Study of TD-9855 to Treat Fibromyalgia

Fibromyalgia

United States
CTI BioPharma

Completed

Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant (PIX-R)

Diffuse Large B-cell Lymphoma | de Novo DLBCL | DLBCL Transformed From Indolent Lymphoma | Follicular Grade 3 Lymphoma

United States, Germany, Italy, United Kingdom, Hungary, France, Spain, Ukraine, Czechia, Austria, Belgium, Bulgaria, Denmark, Poland, Romania, Russian Federation, Slovakia
Theravance Biopharma

Completed

Single Ascending Dose Study of TD-0714 in Healthy Subjects

Healthy

United States
Theravance Biopharma

Completed

TD-1473 for Active Ulcerative Colitis (UC)

Ulcerative Colitis, Active Severe | Ulcerative Colitis, Active Moderate

United States, Georgia, Moldova, Republic of, Romania
Theravance Biopharma

Completed

Single and Multiple Ascending Dose Study of TD-8236 by Inhalation

Asthma

United Kingdom
Theravance Biopharma

Completed

A Study to Assess the Safety, Tolerability and Clinical Activity of TD-1211 in Patients With Opioid-Induced Constipation

Opioid-induced Constipation (OIC)

United States

3

Subscribe